The lead product under development, VT-X7, is a drug-device combination product that has the potential to be the first FDA approved antibiotic therapy for local delivery to treat infected joint prosthesis. If approved, VT-X7 has the potential to improve outcomes and lower the cost of care for orthopedic surgeons and their patients by providing a faster, more reliable treatment option. VT-X7 has undergone extensive pre-clinical development and successfully completed a Phase 2 clinical trial in late 2020.